Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Abuse liability of intra-nasal midazolam in inhaled-cocaine abusers

Texto completo
Autor(es):
Braun, Ivan Mario [1] ; Tavares, Hermano [2] ; de Nucci, Gilberto [3] ; Bernik, Marcio [1]
Número total de Autores: 4
Afiliação do(s) autor(es):
[1] Univ Sao Paulo, Anxiety Disorders Program, Inst & Dept Psychiat, BR-05508 Sao Paulo - Brazil
[2] Univ Sao Paulo, Impulse Control Disorders Program, Inst & Dept Psychiat, BR-05508 Sao Paulo - Brazil
[3] Univ Sao Paulo, Dept Pharmacol, Inst Biomed Sci, BR-05508 Sao Paulo - Brazil
Número total de Afiliações: 3
Tipo de documento: Artigo Científico
Fonte: European Neuropsychopharmacology; v. 18, n. 10, p. 723-728, OCT 2008.
Citações Web of Science: 0
Resumo

Intra-nasally instilled benzodiazepines have been proposed for acute anxiety episodes. However, routes with faster absorption may increase abuse liability. This study compared abuse liability of intra-nasal midazolam between subjects with a history of intra-nasal drug abuse and non-psychiatric subjects on a single-blind randomized controlled trial. Thirty-one inhaled-cocaine abusers and 34 normal volunteers received either 1 mg intra-nasal midazolam or active placebo. Visual analogue scales assessing desire to repeat the experience (ER) and Experience Liking (EL) assessed abuse liability. Profile analysis for repeated measures showed a significant effect of time over ER (F-{[}5,F-57]=3.311, p=0.011) and EL (F-{[}5,F-57]=3.947, p=0.004), diagnostic group (cocaine abusers scoring higher on both - F-{[}5,F-57]=5.229, p=0.026; F-{[}5,F-57]=4.946, p=0.030), regardless of the administered substance. It is concluded that the intra-nasal route does not seem to pose risks for non-psychiatric individuals, but it may represent a risk in itself for subjects with a history of drug abuse through this path. (C) 2008 Elsevier B.V. and ECNP. All rights reserved. (AU)

Processo FAPESP: 97/12461-8 - Potencial de abuso do midazolam administrado por via intranasal em sujeitos normais e usuarios de cocaina.
Beneficiário:Márcio Antonini Bernik
Modalidade de apoio: Auxílio à Pesquisa - Regular